Implications of pharmaceutical industry funding on clinical research

Annals of Pharmacotherapy

Volumn 39, Issue 1, 2005, Pages 194-197

  Lexchin, Joel R ^a,b,c  

^a YORK UNIVERSITY   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; FLUOXETINE; PACLITAXEL; SEROTONIN UPTAKE INHIBITOR; VERAPAMIL;

CLINICAL RESEARCH; COMMERCIAL PHENOMENA; DATA ANALYSIS; DRUG INDICATION; DRUG INDUSTRY; FINANCIAL MANAGEMENT; HUMAN; INTERPERSONAL COMMUNICATION; INVESTMENT; MEDICAL RESEARCH; OVARY CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; REVIEW; RISK BENEFIT ANALYSIS;

BIOMEDICAL AND BEHAVIORAL RESEARCH;

BIOMEDICAL RESEARCH; CLINICAL TRIALS; DRUG INDUSTRY; INFORMATION DISSEMINATION; PUBLISHING; RESEARCH SUPPORT;

EID: 11144232665     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E224     Document Type: Review

References (36)

1. Greenberg DS. Conference deplores corporate influence on academic science. Lancet 2003;362:302-3.
2. Pharmaceutical Research and Manufacturers of America. Industry profile 2003. www.phrma.org/publications/publications/profile02/index.cfm (accessed 2004 Jan 6).
3. Blumenthal D, Gluck M, Louis KS, Stoto MA, Wise D. University-industry research relationships in biotechnology: implications for the university. Science 1986;232:1361-6.
4. Blumenthal D, Campbell EG, Causino N, Louis SK. Participation of life-science faculty in research relationships with industry. N Engl J Med 1996;335:1734-9.
5. Moynihan R. The making of a disease: female sexual dysfunction. BMJ 2003;326:45-7.
6. Tallon D, Chard J, Dieppe P. Relation between agendas of the research community and the research consumer. Lancet 2000;355:2037-40.
7. Dorman PJ, Counsell C, Sandercock P. Reports of randomized trials in acute stroke, 1955 to 1995: what proportions were commercially sponsored. Stroke 1999;30:1995-8.
8. Blumenthal D, Causino N, Campbell E, Louis KS. Relationships between academic institutions and industry in the life sciences - an industry survey. N Engl J Med 1996;334:368-74.
9. Gluck ME, Blumenthal D, Stoto MA. University-industry relationships in the life sciences: implications for students and post-doctoral fellows. Res Policy 1987;16:327-36.
10. Rosenberg SA. Secrecy in medical research. N Engl J Med 1996;334:392-4.
11. Psaty B, Rennie D. Stopping medical research to save money: a broken pact with researchers and patients. JAMA 2003;289:2128-31.
12. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-70.
13. Blumenthal D, Campbell EG, Anderson MS, Causino N, Louis KS. Withholding research results in academic life science: evidence from a national survey of faculty. JAMA 1997;277:1224-8.
14. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363:1341-5.
15. Campbell EG, Louis KS, Blumenthal D. Looking a gift horse in the mouth: corporate gifts supporting life sciences research. JAMA 1998;279:995-9.
16. Bodenheimer T. Uneasy alliance: clinical investigators and the pharmaceutical industry. N Engl J Med 2000;342:1539-44.
17. Stelfox HT, Chua G, O'Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med 1998;338:101-6.
18. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002;287:612-7.
19. Gross DP, Gupta AR, Krumholz HM. Disclosure of financial competing interests in randomised controlled trials: cross sectional review. BMJ 2003;326:526-7.
20. Kjaergard LL, Als-Nielsen B. Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ. BMJ 2002;325:249-52.
21. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 2003;326:1171-3.
22. Huston P, Moher D. Redundancy, disaggregation, and the integrity of medical research. Lancet 1999;347:1024-6.
23. Johansen HK, Gøtzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA 1999;282:1752-9.
24. Clifford TJ, Barrowman NJ, Moher D. Funding source, trial outcome and reporting quality: are they related? Results of a pilot study. BMC Health Services Research 2002;2:18. www.biomedcentral.com/1472-6963/2/18 (accessed 2004 Feb 10).
25. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003;289:454-65.
26. Baker CB, Johnsrud MT, Crismon ML, Rosenheck RA, Woods SW. Quantitative analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry 2003;183:498-506.
27. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA 2003;290:921-8.
28. Bhandari M, Busse JW, Jackowski D, Montori VM, Schünemann H, Sprague S, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ 2004;170:477-80.
29. Rochon PA, Gurwitz JH, Simms RW, Fortin PR, Felson DT, Minaker KL, et al. A study of manufacturer-supported trials of nonsteroidal antiinflammatory drugs in the treatment of arthritis. Arch Intern Med 1994;154:157-63.
30. Safer DJ. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis 2002;190:583-92.
31. Johansen HK, Gotzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA 1999;282:1752-9.
32. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
33. Davidoff F, DeAngelis CD, Drazen JM, Nicholls MG, Hoey J, Hojgaard L, et al. Sponsorship, authorship, and accountability. N Engl J Med 2001;345:825-7.
34. Naylor CD. Early Toronto experience with new standards for industry-sponsored clinical research: a progress report. CMAJ 2002;166:453-6.
35. Schulman KA, Seils DM, Timbic JW, Sugarman J, Dame LA, Weinfurt KP, et al. A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med 2002;347:1335-41.
36. Meier B. Group is said to seek full drug-trial disclosure. New York Times 2004;June 15:A1, C7.